Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
DBV Technologies SA - American (DBVT)
NASDAQ:DBVT
RESEARCH TOOLSreports
Holding DBVT?
Track your performance easily
DBVT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.20 - $9.48
Previous CloseN/A
Volume52.91K
Average Volume (3M)322.14K
Market Cap
$94.39M
Enterprise Value$28.88M
Total Cash (Recent Filing)$196.35M
Total Debt (Recent Filing)$10.50M
Price to Earnings (P/E)―
Beta-0.47
Next Earnings
Mar 06, 2025EPS Estimate
-1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.31
Shares Outstanding20,569,500
10 Day Avg. Volume133,211
30 Day Avg. Volume322,141
Standard Deviation0.27
R-Squared0.02
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.88
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.31
Enterprise Value/Revenue1.59
Enterprise Value/Gross Profit1.84
Enterprise Value/Ebitda-0.19
Forecast
1Y Price Target
$10.00Price Target Upside136.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
DBV Technologies SA - American News
PremiumCompany Announcements
DBV Technologies Reports Positive Phase 3 Study Results
PremiumCompany Announcements
DBV Technologies Amends Executive Severance Agreements
PremiumCompany Announcements
DBV Technologies Aligns with FDA for Viaskin Peanut Approval
Bulls Say, Bears Say
Bulls Say
Clinical TrialsDBV Technologies has exceeded its 600-patient target enrollment in the Phase 3 VITESSE trial, which is the largest interventional peanut allergy trial to date for 4-7 year olds, potentially driving shares higher with expected positive outcomes.
Financial StabilityDBV Technologies ended with $66 million in cash, providing a sufficient financial runway into the first quarter of the next year, supporting its ongoing clinical and regulatory efforts.
Regulatory ProgressManagement is making progress in discussions with the FDA to align on the protocol for the COMFORT safety trials, which could positively impact the study's outcomes and future regulatory approvals.
Bears Say
Cash ReservesDBVT ended with $66M in cash, which is only sufficient to sustain operations until early next year, indicating a need for additional funding.
Funding RequirementsAdditional capital will be required to advance Viaskin Peanut, highlighting potential financial challenges in achieving project milestones.
Operating ExpensesOperating expenses exceeded estimates, driven by unexpectedly high R&D costs, raising concerns about financial management.
---
Ownership Overview
0.82% Insiders
0.09% Mutual Funds
― Other Institutional Investors
99.09% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
DBVT FAQ
What was DBV Technologies SA - American’s price range in the past 12 months?
DBV Technologies SA - American lowest stock price was $2.20 and its highest was $9.48 in the past 12 months.
What is DBV Technologies SA - American’s market cap?
DBV Technologies SA - American’s market cap is $94.39M.
When is DBV Technologies SA - American’s upcoming earnings report date?
DBV Technologies SA - American’s upcoming earnings report date is Mar 06, 2025 which is in 34 days.
How were DBV Technologies SA - American’s earnings last quarter?
DBV Technologies SA - American released its earnings results on Nov 06, 2024. The company reported -$1.6 earnings per share for the quarter, beating the consensus estimate of -$1.8 by $0.2.
Is DBV Technologies SA - American overvalued?
According to Wall Street analysts DBV Technologies SA - American’s price is currently Undervalued.
Does DBV Technologies SA - American pay dividends?
DBV Technologies SA - American does not currently pay dividends.
What is DBV Technologies SA - American’s EPS estimate?
DBV Technologies SA - American’s EPS estimate is -1.11.
How many shares outstanding does DBV Technologies SA - American have?
DBV Technologies SA - American has 20,569,500 shares outstanding.
What happened to DBV Technologies SA - American’s price movement after its last earnings report?
DBV Technologies SA - American reported an EPS of -$1.6 in its last earnings report, beating expectations of -$1.8. Following the earnings report the stock price went down -3.896%.
Which hedge fund is a major shareholder of DBV Technologies SA - American?
Among the largest hedge funds holding DBV Technologies SA - American’s share is Baker Bros Advisors LP. It holds DBV Technologies SA - American’s shares valued at 5M.
---
DBV Technologies SA - American Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (136.97% Upside)
$10.00 (136.97% Upside)
Insider Transactions
Sold Shares
Worth $1.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.11%
12-Months-Change
Fundamentals
Return on Equity
-103.11%
Trailing 12-Months
Asset Growth
-50.97%
Trailing 12-Months
Company Description
DBV Technologies SA - American
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. It focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.
---
DBVT Stock 12 Month Forecast
Average Price Target
$10.00
▲(136.97% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
VistaGen Therapeutics
―
Seres Therapeutics
―
AnaptysBio
―
Xeris Pharmaceuticals
―
Best Analysts Covering DBVT
1 Year
1 Year Success Rate
7/25 ratings generated profit
1 Year Average Return
-24.74%
reiterated a buy rating 21 days ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 28.00% of your transactions generating a profit, with an average return of -24.74% per trade.
---